Lymphoma
Conditions
Brief summary
The purpose of the study is to research the standard and individualized treatment model for relapse and refractory lymphatic system malignant tumors.
Interventions
OTHERHematopoietic stem cell transplantation
Sponsors
Peking University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with relapse and refractory lymphoma and multiple myeloma. 2. At least 1 measurable lesions and its size≥15mm. 3. Patients ≤65 years，no limitations for both gender. 4. ECOG score is 0-1. 5. Life expectancy≥3 months. 6. LVEF≥ 55%; Peripheral blood: WBC ≥ 3.5×10(9)/L,neutrophil ≥1.5×10(9)/L, PLT≥75×109/L，Hb≥90g/L; Renal function: Cr≤2.0×UNL; Liver function: BIL≤2.0×UNL，ALT/AST≤2.5×UNL; 7. Written informed consent are acquired.
Exclusion criteria
1. Previously received stem cell transplantation. 2. Women with pregnant, lactating or not to take contraceptive measures. 3. Severe acute infection or suppurative and chronic infection that wound not healing. 4. Severe heart failure. 5. Suffering from mental disorders and poor compliance. 6. Other situations that investigators consider as contra-indication for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate | 2 years after treatment |
| complete response | 2 years after treatment |
| progression-free survival | 2 years after treatment |
| overall survival | 2 years after treatment |
Countries
China
Contacts
Primary ContactZhu Jun, archiater
Outcome results
None listed